



The
Patent
Office

PCT/EP 98/02138

09/402273

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP9 1RH

REC'D	25 MAY 1998
WIPO	PCT

PRIORITY DOCUMENT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.


In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed *Alastair J.*

Dated *26th March 1998*



2d, 2e and 2f: If there are further applicants please provide details on a separate sheet of paper

Second applicant (if any)

2d If you are applying as a corporate body please give:
Corporate Name

Country (and State of
Incorporation, if appropriate)

2e If you are applying as an individual or one of a partnership please give in full:

Surname:

Forenames:

2f In all cases, please give the following details:

Address:

UK postcode

(if applicable)

Country

ADP number

(if known)

3 An address for service in the
United Kingdom must be supplied

Please mark correct box.

3 **Address for service details**

3a Have you appointed an agent to deal with your application?

Yes

No  go to 3b



please give details below

Agent's name

WEST, Vivien

Agent's address:

CORPORATE INTELLECTUAL PROPERTY
SMITHKLINE BEECHAM PLC
2 NEW HORIZONS COURT
GREAT WEST ROAD
BRENTFORD
MIDDLESEX

Postcode

TW8 9EP

Agent's ADP

4385316004

number

3b: If you have appointed an agent, all
correspondence
concerning your
application will be sent to
the agent's United
Kingdom address.

3b If you have not appointed an agent please give a name and address in the
United Kingdom to which all correspondence will be sent:

Name:

Address

Postcode

Daytime telephone
number (if available)

ADP number
(if known)

④ Reference number

P31786

4. Agent's or
applicant's reference
number (if applicable)

⑤ Claiming an earlier application date

5. Are you claiming that this application be treated as having been filed on the date of filing of an earlier application?

*Please mark correct box*Yes No  [go to 6](#)*please give details below*

number of earlier
application or patent
number

filing date (day month year)

and the Section of the Patents Act 1977 under which you are claiming:

15(4) (Divisional) 8(3) 12(6) 37(4)

Please mark correct box

⑥ If you are declaring priority from a PCT Application please enter 'PCT' as the country and enter the country code (for example, GB) as part of the application number

Please give the date in all number format, for example, 31/05/90 for 31 May 1990

⑥ Declaration of priority

6. If you are declaring priority from previous application(s), please give:

Country of Filing	Priority application number (if known)	Filing Date (day, month, year)

7

- any applicant is not an inventor
- there is an inventor who is not
- an applicant, or
- any applicant is a corporate body.

7 Inventorship

7. Are you (the applicant or applicants) the sole inventor or the joint inventors?

Please mark correct box

Yes No A Statement of Inventorship on Patents form 7/77 will need to be filed (see Rule 15.).

8 Please supply duplicates of claim(s), abstract, description and drawings).

8 Checklist

8a Please fill in the number of sheets for each of the following types of document contained in this application

Continuation sheets for this Patents Form 1/77

Claim(s)	1	Description	6
Abstract		Drawing(s)	

8b Which of the following documents also accompanies the application?

Priority documents (please state how many)

Translation(s) of Priority documents (please state how many)

Patents Form 7/77 - Statement of Inventorship and Right to Grant

Patents Form 9/77 - Preliminary Examination Report

Patents Form 10/77 - Request for Substantive Examination

Please mark correct box(es)

9 You or your appointed agent (see Rule 90 of the Patents Rules 1990) must sign this request.

Please sign here ➡

Signed Vivien West Date: 04 04 1997
(day month year)

A completed fee sheet should preferably accompany the fee.

Please return the completed form, attachments and duplicates where requested, together with the prescribed fee to either;

The Comptroller or The Comptroller
The Patent Office The Patent Office
Cardiff Road 25 Southampton Buildings
Newport London
Gwent WC2A 1AY
NP9 1RH

Formulation

This invention relates to novel formulations for use in desensitisation therapy of allergy sufferers.

5 It is known that desensitisation therapy results in a changed immunological response specific for the allergens administered. Such changes are considered to be responsible for the beneficial effects of the treatment and amelioration of the symptoms of allergy.

10 The immunological changes responsible for benefit are not entirely understood. Although a raised allergen specific IgG antibody response is considered to be a desirable outcome of therapy, it is now believed that certain changes in the allergen specific T cell (T lymphocyte) response are more important.

15 Two subclasses of T cell, TH1-like and TH2-like interact with one another via various messenger molecules. In an allergic subject it appears that there is a greater allergen specific TH2 than a TH1 activity. This can lead to a high allergen specific IgE antibody level and greater eosinophil activity. These are two important components of the allergic syndrome.

A change in the above situation to one where there is greater allergen specific TH1 rather than TH2 activity is thought to be an important component of immunotherapy leading to a clinical benefit.

20 GB-A-1 377 074 describes a process for preparing coprecipitates of tyrosine having an allergen dispersed therein.

25 GB-A-1 492 973 describes a process for preparing coprecipitates of tyrosine having a modified allergen dispersed therein. The allergen has been modified by treatment with an agent, such as glutaraldehyde, which causes intra-molecular cross-linking and reduces the allergenicity of the product relative to the unmodified allergen.

30 3 De-O-acylated monophosphoryl lipid A (hereinafter 3-DMPL or "MPL") is known from GB 2220211 (Ribi). Chemically it is a mixture of 3 De-O-acylated monophosphoryl lipid A with 4, 5 or 6 acylated chains and is manufactured by Ribi Immunochem Montana. A preferred form of 3 De-O-acylated monophosphoryl lipid A is disclosed in International Patent Application No. 92/116556. 3-DMPL is an example of a substance that can enhance the TH1 over TH2 directing properties of administered allergens.

According to the present invention there is provided a pharmaceutical composition comprising tyrosine, an optionally modified allergen, and 3-DMPL. Typically, the allergen is coated with and /or adsorbed onto tyrosine, for example by co-precipitation or mixing.

35 The 3-DMPL can be mixed with the other components of the composition prior to administration. Alternatively it can be formulated together with the other components during manufacture of the product. Alternatively, it can be administered at a different site or time

than the other components. Administration can be by a number of routes including parenteral and enteral.

5 A further aspect of the invention thus provides a method of treating a patient who is susceptible to allergy, which method comprises administering to the said patient an effective amount of tyrosine, an optionally modified allergen, and 3-DMPL.

A further aspect of the invention provides use of tyrosine, an optionally modified allergen, and 3-DMPL, in the preparation of a medicament for use in the prevention or treatment of allergy.

10 The allergen may be derived from any allergy causing substance, such as a pollen (e.g. ragweed or birch pollen), food, insect venom, mould, animal fur, or house dust mite (*D. farinae* or *D. pteronyssinus*). As used herein, "allergen" includes a mixture of allergens which may be from a single source or more than one source. The term "allergen" also includes peptides containing one or more epitopes of an allergen, such as allergen fragments, prepared by total synthesis, by enzymatic degradation of allergens, or by other means.

15 The allergen is optionally modified by reaction with a cross-linking agent such as a dialdehyde, more particularly glutaraldehyde.

A further aspect of the invention provides a process for the preparation of a pharmaceutical composition in accordance with the invention, which process comprises (a) (optionally) modifying an allergen by reaction with a cross-linking agent, (b) mixing an 20 aqueous solution of the optionally modified allergen with a solution of tyrosine in a strong aqueous acid, (c) neutralising the mixture of solutions, thereby co-precipitating tyrosine and modified allergen, (d) mixing the product with 3-DMPL, and (e) optionally, adding a physiologically acceptable carrier.

25 Suitable physiologically acceptable carriers include phenol-saline and sterile water. Typically, the allergen is modified by treatment with a dialdehyde such as glutaraldehyde, in aqueous solution at a pH of between 5 and 10, typically about 7, and a temperature of between 0 and 100 °C, more usually between 4 and 37 °C, for up to 10 hours, for example about two hours at room temperature. The ratio of allergen to glutaraldehyde is typically in the range 50:1 to 2:1, for example about 10:1.

30 The intermediate can be freeze dried or used in the next stage.

A solution of the modified allergen, typically at pH 7±1, obtained either as the reaction mixture from the cross-linking process or from the solvation of a solid, is then mixed with a solution of tyrosine in a strong aqueous acid. The strong acid is usually an inorganic acid, preferably hydrochloric acid. The solution of allergen used in this step 35 typically contains between 0.1 µg/ml and 1000 µg/ml allergen protein, for example about 400µg/ml. The ratio of allergen: tyrosine in the mixture is typically in the range 1:4 x 10⁵ to 1:1 x 10² w/w.

The resulting mixture of solutions of allergen and tyrosine is neutralised. By neutralisation is meant an adjustment of pH to a value within the range 4.0 to 7.5. It is important that, at no time, or at least at no prolonged time, during the neutralisation does the pH of the solution rise appreciably above 7.5. This condition can be met by vigorous stirring of the solution and by the use only of the required amount of base, if desired. Various buffering agents can usefully be added to the solutions of allergen to assist in pH control during the mixing and neutralising stages.

A particularly useful method of carrying out the neutralisation is for separate streams of the solution of tyrosine in acid and the neutralising base to be run into the solution of allergen. The rates of flow of the added solutions are controlled by pH-state, that is by equipment which regulates the flow of one or both of the solutions so that the pH of the reaction mixture remains substantially constant at a predetermined level. We have found that optimum results are usually obtained by pH control within the range 6.5 to 7.5 though the precise pH may vary according to the nature of the allergen.

The result of the neutralisation is the immediate precipitation of the tyrosine, within and/or upon which the solution of allergen is occluded and/or adsorbed. After the precipitation the mixture is either washed immediately or allowed to stand for a period of from a few hours to a day or two prior to washing.

The resulting precipitate may be removed from the solution by centrifugation or filtration and washed, e.g. with phenol-saline, before being resuspended in a physiologically-acceptable carrier such as phenol-saline, or sterile water, to produce an injectable composition suitable for use in desensitisation therapy in combination with 3-DMPL.

MPL which has been dissolved by the method described in Preparation 3 below or by sonication can be diluted by various means prior to its addition to tyrosine adsorbates of allergens or modified allergens. The preparation of MPL is initially made at a concentration of typically between 0.5mg per ml and 4 mg per ml, for example 1 mg per ml. It can then be diluted to a concentration of between 500 μ g per ml and 20 μ g per ml, preferably about 100 μ g per ml. This dilution can be made in pure water, or in an aqueous glycerol solution containing between 1% and 4 %, preferably 2 %, glycerol. Such dilutions can then be added to a suspension of the tyrosine adsorbate prepared as described above. For convenience, the concentration of the MPL solution and the tyrosine adsorbate suspension respectively may be selected such that approximately equal volumes of each are admixed to obtain the final product for injection. A typical final product contains about 100 μ g per ml of allergen and about 250 μ g per ml of MPL.

The following Example illustrates the present invention:

Preparation 1

5

A neutral solution of approximately 0.5 mg/ml grass pollen extract which had been partially purified by dialysis or fractionation was chemically modified by the addition of an equal volume of 0.25% w/v glutaraldehyde and the mixture stirred for approximately 2 hours at room temperature. To the above mixture was added phosphate buffer solution at a pH of 7 ±1. The allergen solution was co-precipitated with tyrosine by the simultaneous addition of one volume of L-tyrosine in HCl (prepared by dissolving 24g L-tyrosine to 100ml with 3.8M HCl) and one volume of 3.2M NaOH, to four volumes of allergen solution, with vigorous agitation. The suspension so formed was centrifuged, washed repeatedly with buffered saline to remove contaminants and resuspended to the original volume in buffered saline pH6 ±1.

10 15 3-DMPL suitable for coadministration with the above formulation was prepared as described in Preparation 3 below.

Preparation 2

20 Eight mg of ovalbumin (XOA) were dissolved by mixing in 20ml of EVANS solution. Next 6.9ml of phosphate buffer were added with mixing. The solution was placed in a 100ml beaker containing a magnetic stir bar. While mixing using a magnetic stirrer, 6.9ml of 3.2N NaOH and 6.9ml of 3.8N HCL containing 24% W/V-tyrosine were added simultaneously, dropwise, over a period of 5 min. to form a precipitate. The mixture was 25 allowed to stir for an additional 5 min. and then transferred to a 50ml centrifuge tube and centrifuged for 10 min. at 2500 rpm. After centrifugation the supernatant was decanted and the pelleted precipitate resuspended in 40ml of phosphate buffer. The mixture was centrifuged for 5 min. at 2500 rpm. After centrifugation the supernatant was decanted and the precipitate resuspended in 40ml of phosphate buffer. The mixture was centrifuged for 5 30 min. at 2500 rpm. After centrifugation the supernatant was decanted and the pelleted precipitate resuspended in 40ml of phosphate buffer saline, pH7.2, containing 0.4% V/V glycerol and 0.01% W/V thimerosal as a preservative. The final product contained approximately 40mg/ml of tyrosine adsorbate. Assuming 100% binding of the XOA to the tyrosine adsorbate the XAO was at 200µg/ml in the final product. The XOA-tyrosine 35 adsorbate was stored at 4°C until needed.

Preparation 3

A 4 mg/ml solution of 1,2-dipalmitoyl-SN-glycero-3-phospho choline (DPPC) in absolute ethanol was prepared. For each 1.0mg of MPL®-TEA salt to be solubilized, 27 μ l of DPPC were added to dissolve the MPL®. The ethanol was removed by blowing a stream of N₂ gently into the vial. Next 1.0ml of pyrogen-free water for injection was added for each mg of MPL® in the dried MPL® /DPPC mixture. The solution was sonicated in a bath sonicator at 60-70°C until clear. The MPL®/DPPC solution was then filter sterilized by filtration through a SFCA 290-4520 Nalgene 0.2 μ m filter. The MPL®/DPPC solution was 10 aseptically dispensed at 1.0mg/ml into depyrogenated vials, labelled MPL®-AF, and stored at 4°C.

Biological activity

15 TH1 inducing activity in mice can be equated with the production of IgG2a and IgG2b antibodies and the TH2 inducing activity with the production of IgG1 antibodies and IgE antibodies.

20 Therefore, as an example, an experiment was carried out in mice to demonstrate the profiles of the allergen specific antibodies to an exemplar allergen ovalbumen (XOA) which is a well-known food allergen derived from chicken eggs. It was confirmed that a formulation consisting of MPL + XOA+tyrosine stimulated a more advantageous antibody profile than MPL + XOA, XOA+tyrosine or XOA alone.

Groups of 8 BALB/c female mice, 6-8 weeks of age, were injected subcutaneously in the inguinal area with 0.2ml of one of the following vaccines:

25 XOA+Tyrosine: The XOA tyrosine adsorbate prepared in Preparation 2 above was diluted with an equal volume of phosphate buffered saline within 30 min. prior to injection.

30 XOA+Tyrosine+MPL: The XOA tyrosine adsorbate prepared in Preparation 2 above was diluted with an equal volume of MPL®-AF at 500 μ g/ml in phosphate buffered saline within 30 min. prior to injection.

35 XOA+MPL: XOA was dissolved in phosphate buffered saline at 200 μ g/ml and diluted with an equal volume of MPL®-AF at 500 μ g/ml in phosphate buffered saline within 30 min. prior to injection.

XOA Alone: XOA was dissolved at 200 μ g/ml in phosphate buffered saline and diluted with an equal volume of phosphate buffered saline.

Twenty-one days later the four groups of mice were boosted with 0.2ml of freshly prepared vaccines. Fourteen days following the booster the mice were bled and the sera separated and stored at -70°C until assay.

5 The sera were assayed by conventional ELISA technique using horseradish conjugated goat anti-mouse IgG₁, IgG_{2a}, and IgG_{2b} antibodies purchased from Southern Biotechnology, Inc. (Birmingham, AL) and used according to the manufacturer's instruction. The IgG₁, IgG_{2a}, and IgG_{2b} titers represent the reciprocal serum dilution giving a reading of >0.1 OD units at A₄₉₀. The serum IgE levels were measured using an anti-IgE capture

10 10 ELISA followed by the use of a biotinylated ovalbumin probe. Binding was measured following the addition of a horseradish conjugated strepavidin preparation. The results are reported as OD units at A₄₉₀.

RESULTS

15

Formulation	IgG1 Titer	IgG2a Titer	IgG2b Titer	IgE Titer
Allergen + tyrosine	102400	100	200	0.213
Allergen + tyrosine + MPL	409600	102400	102400	0.104
Allergen + tyrosine + MPL + LPS	102400	200	400	0.218
Allergen + tyrosine + LPS	6400	<100	<100	0.235
Normal saline	<100	<100	<100	0.095
Control (water)				

Of particular importance is the fact that the combination of allergen + tyrosine + MPL induces less allergen specific IgE antibody than the other combinations. Furthermore, the ratio of IgG2a or IgG2b to IgG1 antibodies is greater and consistent with the highest levels

20 of the two former antibody isotypes seen in the experiment in the mice given allergen+tyrosine+MPL than in any other group of mice. This is indicative of a better ratio of TH1 cell induction over TH2 cell induction in this group compared with that induced in the other groups of mice.

Claims

1. A pharmaceutical composition comprising tyrosine, an optionally modified allergen,
5 and 3-DMPL.
2. A composition according to claim 1, wherein the allergen is coated with and /or adsorbed onto tyrosine.
- 10 3. A method of treating a patient who is susceptible to allergy, which method comprises administering to the said patient an effective amount of tyrosine, an optionally modified allergen, and 3-DMPL.
- 15 4. Use of tyrosine, an optionally modified allergen, and 3-DMPL, in the preparation of a medicament for use in the prevention or treatment of allergy.
- 20 5. A process for the preparation of a pharmaceutical composition according to claim 1 or 2, which process comprises (a) (optionally) modifying an allergen by reaction with a cross-linking agent, (b) mixing an aqueous solution of the optionally modified allergen with a solution of tyrosine in a strong aqueous acid, (c) neutralising the mixture of solutions, thereby co-precipitating tyrosine and modified allergen, (d) mixing the product with 3-DMPL, and (e) optionally, adding a physiologically acceptable carrier.

